WallStSmart

Autonomix Medical, Inc. Common Stock (AMIX)vsEdwards Lifesciences Corp (EW)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

EW leads profitability with a 15.3% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 54/100 (C-).

AMIX

Avoid

23

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.8
Piotroski: 1/9Altman Z: -16.76

EW

Buy

54

out of 100

Grade: C-

Growth: 5.3Profit: 8.0Value: 5.3Quality: 8.5
Piotroski: 3/9Altman Z: 4.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMIX.

EWUndervalued (+69.2%)

Margin of Safety

+69.2%

Fair Value

$257.48

Current Price

$105.80

$151.68 discount

UndervaluedFair: $257.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMIX1 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

EW4 strengths · Avg: 9.8/10
Operating MarginProfitability
30.1%10/10

Strong operational efficiency at 30.1%

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Market CapQuality
$59.81B9/10

Large-cap with strong market position

Areas to Watch

AMIX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.55M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
60.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : AMIX

The strongest argument for AMIX centers on Price/Book.

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 15.3% and operating margin at 30.1%. Revenue growth of 10.5% demonstrates continued momentum.

Bear Case : AMIX

The primary concerns for AMIX are Revenue Growth, EPS Growth, Market Cap.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 60.5x leaves little room for execution misses.

Key Dynamics to Monitor

AMIX profiles as a value stock while EW is a mature play — different risk/reward profiles.

EW carries more volatility with a beta of 0.83 — expect wider price swings.

EW is growing revenue faster at 10.5% — sustainability is the question.

EW generates stronger free cash flow (507M), providing more financial flexibility.

Bottom Line

EW scores higher overall (54/100 vs 23/100), backed by strong 15.3% margins and 10.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Autonomix Medical, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company is headquartered in The Woodlands, Texas.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?